Steve Duffy, Author at MPR

Steve Duffy

Digital Content Editor

All articles by Steve Duffy

‘Potentially Concerning’ Signal Identified in Long-Term Follow-up Data Involving Paclitaxel-Coated Products


A preliminary analysis of long-term follow-up data (up to 5 years) involving patients with peripheral arterial disease (PAD) treated with paclitaxel-coated products revealed a ‘potentially concerning’ signal of increased long-term mortality when compared with those treated with uncoated devices, according to the Food and Drug Administration (FDA). Among the 3 trials that included 5-year follow-up…

FDA to Review Fedratinib for the Treatment of Myelofibrosis


The Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application (NDA) for fedratinib (Celgene), an investigational agent being developed for the treatment of myelofibrosis (MF). Fedratinib is an oral kinase inhibitor with activity against wild type and mutationally activated Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3).…